Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more
Applied Therapeutics Inc (APLT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 32.800x
Based on the latest financial reports, Applied Therapeutics Inc (APLT) has a cash flow conversion efficiency ratio of 32.800x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.40 Million) by net assets ($-561.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Applied Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Applied Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jenkongklai PCL
BK:JPARK
|
0.061x |
|
Wijaya Karya Beton
JK:WTON
|
0.038x |
|
AGAT EJENDOMME NAM. DK 1
F:2TD
|
N/A |
|
CryoCell International Inc
NYSE MKT:CCEL
|
-0.171x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
Tron Inc.
NASDAQ:TRON
|
-0.004x |
|
SAGA PURE ASA NK 1
F:SAT
|
N/A |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
-0.249x |
Annual Cash Flow Conversion Efficiency for Applied Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Applied Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.01 Million | $-84.31 Million | -1.479x | -145.96% |
| 2023-12-31 | $-17.15 Million | $-55.17 Million | 3.218x | +116.73% |
| 2022-12-31 | $4.06 Million | $-78.09 Million | -19.230x | -1225.53% |
| 2021-12-31 | $62.54 Million | $-90.73 Million | -1.451x | -51.99% |
| 2020-12-31 | $81.94 Million | $-78.21 Million | -0.954x | +14.28% |
| 2019-12-31 | $32.61 Million | $-36.31 Million | -1.113x | -57.51% |
| 2018-12-31 | $15.82 Million | $-11.18 Million | -0.707x | -187.64% |
| 2017-12-31 | $-3.96 Million | $-3.19 Million | 0.807x | -- |